Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM (opens in a new tab)

prnewswire.com · 2025-06-22

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One key claim is not backed by the study. 4 other points were not covered by the paper.

  • 3 supported
  • 1 not supported
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

prnewswire.com · 2025-06-22

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Mixed

One claim isn't supported by the study. Three of eight check out. Four claims the study doesn't address.

  • 3 supported
  • 1 not supported
  • 4 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not supportedNovo Nordisk says the REDEFINE clinical program will continue, including a recently initiated REDEFINE 11 trial, to further investigate efficacy and safety of CagriSema.View evidenceHide evidence

Why this verdict

The supplied paper profile concerns REDEFINE 1 efficacy and safety at 68 weeks and does not provide evidence about continuation of the broader REDEFINE program or the initiation of REDEFINE 11.

Claim 2 of 8Not coveredIn REDEFINE 1, treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group if all patients adhered to treatment.View evidenceHide evidence

As stated22.7% mean weight reduction

Why this verdict

The abstract-level profile reports the treatment-policy/ITT-consistent estimate of −20.4% versus −3.0%, not the adherence-based or trial-product estimand values of 22.7% versus 2.3%. This magnitude may require full-text or supplementary evidence not available at abstract depth.

1

Study evidence

CagriSema vs placebo: mean percent change in body weight from baseline to week 68 was −20.4% vs −3.0% (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001).-17.3 percentage points (95% CI -18.1 to -16.6)

“In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes”
Claim 3 of 8Not coveredA supportive secondary analysis showed that 50.7% of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI <30 kg/m2) at the end of treatment, compared with 10.2% in the placebo group.View evidenceHide evidence

As stated50.7% reached BMI <30 kg/m2

Why this verdict

The abstract profile does not report the supportive BMI-transition analysis or the stated proportions reaching BMI <30 kg/m2. It supports large weight loss generally, but this specific secondary analysis is not available at abstract depth.

1

Study evidence

CagriSema vs placebo: mean percent change in body weight from baseline to week 68 was −20.4% vs −3.0% (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001).-17.3 percentage points (95% CI -18.1 to -16.6)

“In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes”
Claim 4 of 8Not coveredSelect confirmatory secondary endpoints showed that 40.4% of those receiving CagriSema achieved a body-weight reduction of at least 25%, and 23.1% lost at least 30% of their body weight, when all participants adhered to treatment.View evidenceHide evidence

As stated40.4% ≥25% weight loss; 23.1% ≥30% weight loss

Why this verdict

The abstract profile says proportions achieving ≥20%, ≥25%, and ≥30% weight loss were confirmatory secondary endpoints and were higher with CagriSema versus placebo, but it does not provide the stated exact proportions or an adherence-based estimand for them.

1

Study evidence

CagriSema vs placebo: mean percent change in body weight from baseline to week 68 was −20.4% vs −3.0% (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001).-17.3 percentage points (95% CI -18.1 to -16.6)

“In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes”
Claim 5 of 8Not coveredThe release says safety data from REDEFINE 1 and 2 were comparable with the GLP-1 RA class, with low discontinuation rates due to adverse events.View evidenceHide evidence

As stated6% discontinuation with CagriSema vs 3.7% with placebo in REDEFINE 1

Why this verdict

The profile supports that gastrointestinal adverse events were more frequent with CagriSema and mainly transient and mild-to-moderate, but it does not report discontinuation rates, class-comparability conclusions, or REDEFINE 2 safety data. The stated 6% versus 3.7% discontinuation rate is not verifiable from the abstract profile.

1

Study evidence

Gastrointestinal adverse events occurred in 79.6% of participants receiving cagrilintide–semaglutide versus 39.9% with placebo; events listed included nausea, vomiting, diarrhea, constipation, and abdominal pain and were described as mainly transient and mild-to-moderate in severity.79.6% vs 39.9%

“Safety was assessed.”
Claim 6 of 8SupportedNEJM published results from Novo Nordisk's phase 3 REDEFINE 1 trial of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.View evidenceHide evidence

Why this verdict

The abstract profile supports that REDEFINE 1 was a phase 3a, 68-week trial in adults without diabetes with obesity or overweight plus at least one obesity-related complication, testing CagriSema alongside lifestyle intervention for weight loss. The supplied profile does not independently detail journal metadata, but the scientific trial description is supported.

1

Study evidence

CagriSema vs placebo: mean percent change in body weight from baseline to week 68 was −20.4% vs −3.0% (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001).-17.3 percentage points (95% CI -18.1 to -16.6)

“In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes”
Claim 7 of 8SupportedREDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.View evidenceHide evidence

Why this verdict

The profile states the coprimary endpoints were percent body-weight change and achieving at least 5% weight loss at week 68, and reports statistically significant superiority versus placebo. The causal framing is appropriate for a randomized controlled trial.

1

Study evidence

CagriSema vs placebo: mean percent change in body weight from baseline to week 68 was −20.4% vs −3.0% (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001).-17.3 percentage points (95% CI -18.1 to -16.6)

“In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes”
Claim 8 of 8SupportedWhen evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved weight loss of 20.4% at 68 weeks versus 3.0% for placebo.View evidenceHide evidence

As stated20.4% mean weight reduction

Why this verdict

The profile directly reports mean percent body-weight change at week 68 of −20.4% with CagriSema versus −3.0% with placebo under the treatment-policy estimand, consistent with evaluating treatment effect regardless of adherence.

1

Study evidence

CagriSema vs placebo: mean percent change in body weight from baseline to week 68 was −20.4% vs −3.0% (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001).-17.3 percentage points (95% CI -18.1 to -16.6)

“In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • REDEFINE 1 was a phase 3a, 68-week randomized, double-blind, placebo- and active-controlled trial of CagriSema versus placebo and active comparators, with lifestyle intervention given to all groups.

    The story reflects the phase 3 trial, placebo comparison, and lifestyle intervention, but it does not mention randomization, double blinding, or active comparator arms, which are important design features supporting causal interpretation.

    From Phase 3a randomized, double-blind, placebo- and active-controlled parallel-group trial

  • The abstract profile provides limited safety detail and does not report serious adverse events, treatment discontinuations due to adverse events, detailed grading, timing, or adjudication procedures.

    The story reports low discontinuation rates, but the abstract profile specifically lacks discontinuation data and detailed safety tables, making this an interpretation-relevant limitation that is not acknowledged.

    From Phase 3a randomized, double-blind, placebo- and active-controlled trial (68 weeks)

6 things the story did carry across
  • The enrolled population was adults without diabetes with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 plus at least one obesity-related complication.
  • Coprimary endpoints were percent change in body weight and achieving at least 5% body-weight reduction at week 68 versus placebo.
  • The abstract’s main reported efficacy estimate used the treatment-policy estimand, consistent with an intention-to-treat principle: −20.4% body-weight change with CagriSema versus −3.0% with placebo.
  • The abstract reports confirmatory secondary responder endpoints for ≥20%, ≥25%, and ≥30% weight loss and states that CagriSema was superior to placebo, but it does not provide exact proportions in the abstract profile.
  • The REDEFINE 1 trial excluded adults with diabetes; results apply to the non-diabetes trial population rather than to patients with type 2 diabetes.
  • Funding was disclosed as Novo Nordisk, creating a potential sponsor-influence limitation noted in the profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate the efficacy of coadministered cagrilintide 2.4 mg + semaglutide 2.4 mg (CagriSema) versus placebo (and versus active comparators) for weight loss at 68 weeks in adults with overweight/obesity without diabetes, alongside lifestyle intervention.Phase 3a randomized, double-blind, placebo- and active-controlled parallel-group trialExpand

In plain English

Phase 3a, 68-week, randomized, double-blind, placebo- and active-controlled trial (REDEFINE 1) in adults without diabetes and with BMI ≥30 or BMI ≥27 plus ≥1 obesity-related complication evaluated coadministration of cagrilintide 2.4 mg + semaglutide 2.4 mg (CagriSema) versus placebo (and versus semaglutide alone and cagrilintide alone) alongside lifestyle intervention. The combination produced a mean percent weight change of −20.4% at week 68 versus −3.0% with placebo (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001) and higher proportions of participants achieving ≥5%, ≥20%, ≥25%, and ≥30% weight loss. Gastrointestinal adverse events were more frequent with the combination (79.6% vs 39.9% with placebo) and were described as mainly transient and mild-to-moderate.

Key findings

  • CagriSema vs placebo: mean percent change in body weight from baseline to week 68 was −20.4% vs −3.0% (estimated difference −17.3 percentage points; 95% CI −18.1 to −16.6; P<0.001).-17.3 percentage points (95% CI -18.1 to -16.6)
  • CagriSema increased proportions of participants reaching prespecified responder thresholds (≥5%, ≥20%, ≥25%, ≥30% weight loss) at week 68 versus placebo (P<0.001 for all comparisons).
“In a phase 3a, 68-week, multicenter, double-blind, placebo-controlled and active-controlled trial, we enrolled adults without diabetes”
What this piece can’t prove
  • Trial population excluded adults with diabetes (results apply to adults without diabetes as enrolled).
  • Funding disclosed (Novo Nordisk); potential influence noted in abstract.

1 further detail could not be confirmed from the summary.

2human in vivoAssess the safety/tolerability of CagriSema versus placebo/active comparators over 68 weeks, with emphasis on gastrointestinal adverse events.Phase 3a randomized, double-blind, placebo- and active-controlled trial (68 weeks)Expand

In plain English

In the REDEFINE 1 phase 3a randomized, double-blind, placebo- and active-controlled trial (68 weeks) of adults without diabetes and with overweight or obesity, cagrilintide plus semaglutide (CagriSema) had a substantially higher reported incidence of gastrointestinal adverse events than placebo (79.6% vs. 39.9%); gastrointestinal events (nausea, vomiting, diarrhea, constipation, abdominal pain) were described as mainly transient and mild-to-moderate in severity. Safety was assessed across the randomized trial population.

Key findings

  • Gastrointestinal adverse events occurred in 79.6% of participants receiving cagrilintide–semaglutide versus 39.9% with placebo; events listed included nausea, vomiting, diarrhea, constipation, and abdominal pain and were described as mainly transient and mild-to-moderate in severity.79.6% vs 39.9%
“Safety was assessed.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 40 candidate papers

And 34 more candidates considered.